.Attribute Medication, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medicine conjugate (ADC) tisotumab vedotin resulted in boosted progression-free and general survival, bring about FDA approval as well as a brand new procedure possibility for patients.